<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39433814</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity of Comirnaty Omicron XBB.1.5 booster COVID-19 mRNA vaccine in long-term survivors after allogeneic hematopoietic stem cell transplantation.</ArticleTitle><Pagination><StartPage>24749</StartPage><MedlinePgn>24749</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24749</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-74712-x</ELocationID><Abstract><AbstractText>Primary mRNA vaccination against COVID-19 typically involves three doses for immunocompromised individuals, including hematopoietic stem cell transplantation (allo-HSCT) recipients. However, optimal subsequent boosting strategies remain unclear. This study aimed to assess the immunogenicity of a booster dose using the most recently updated vaccine (Comirnaty Omicron XBB.1.5) among long-term allo-HSCT survivors having previously received multiple mRNA vaccine doses, in median 4 (2-6). Thirty-four allo-HSCT recipients were enrolled at Sahlgrenska University Hospital, and peripheral blood samples were collected immediately before and four weeks after booster. Antibodies against the receptor-binding domain (anti-RBD) of spike 1 (S1) and nucleocapsid, as well as S1-specific ex vivo T-cell responses, were evaluated. Adverse events were monitored. Despite a median of 13 months since the prior vaccine dose, both humoral and T-cell responses against S1 were present in the pre-booster samples in all but two participants, who suffered from severe chronic Graft-versus-host disease. Notably, 62% of participants had a previously confirmed COVID-19 infection. Significantly higher pre-booster antibody levels were observed in women than men (p = 0.003). Booster dosing strengthened specific antibody and T cell responses and equalized pre-booster gender differences, although responses remained significantly lower among those receiving immunosuppressive treatment (p = 0.041). In a population of long-term allo-HSCT survivors, the majority of whom had a prior confirmed COVID-19 infection, both pre- and post-booster immune responses were robust. However, patients undergoing immunosuppressive treatment for GvHD exhibited significantly weaker responses.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Einarsdottir</LastName><ForeName>Sigrun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. sigrun.einarsdottir@vgregion.se.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Dury</LastName><ForeName>Samer</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fridriksson</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andius</LastName><ForeName>Linn Dahlsten</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharba</LastName><ForeName>Sinan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mountagui</LastName><ForeName>Amin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waern</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Hepatology, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ringlander</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region Västra Götaland, Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martner</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hellstrand</LastName><ForeName>Kristoffer</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Region Västra Götaland, Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>TIMM Laboratory, Sahlgrenska Center for Cancer Research, Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waldenström</LastName><ForeName>Jesper</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lagging</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Region Västra Götaland, Department of Clinical Microbiology, Sahlgrenska University Hospital, Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000087503">mRNA Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="Y">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="Y">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017741" MajorTopicYN="N">Survivors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="N">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014184" MajorTopicYN="N">Transplantation, Homologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000087503" MajorTopicYN="N">mRNA Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39433814</ArticleId><ArticleId IdType="pmc">PMC11494131</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-74712-x</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-74712-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chen, P. et al. Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: A one-year follow-up of the prospective clinical trial COVAXID. EBioMedicine. 94, 104700 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10365982</ArticleId><ArticleId IdType="pubmed">37453361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, T. Y. et al. Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies. J. Microbiol. Immunol. Infect. (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38480093</ArticleId></ArticleIdList></Reference><Reference><Citation>Einarsdottir, S. et al. Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation. Haematologica. 107(6), 1479–1482 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9152965</ArticleId><ArticleId IdType="pubmed">35236057</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, M. et al. A third dose COVID-19 vaccination in allogeneic hematopoietic stem cell transplantation patients. Vaccines (Basel); 10(11). (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9695068</ArticleId><ArticleId IdType="pubmed">36366338</ArticleId></ArticleIdList></Reference><Reference><Citation>Rubin, M. et al. Efficacy of SARS-CoV-2 vaccine doses in allogeneic hemopoietic stem cell recipients: a systematic review and Meta-analysis. Asian Pac. J. Cancer Prev.25(2), 393–399 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11077108</ArticleId><ArticleId IdType="pubmed">38415523</ArticleId></ArticleIdList></Reference><Reference><Citation>Piñana, J. L. et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplant. :1–14. (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9974060</ArticleId><ArticleId IdType="pubmed">36854892</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevallier, P. et al. Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients. Hematol. Oncol.40(5), 1097–1099 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9087413</ArticleId><ArticleId IdType="pubmed">35468662</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordat, J., Maury, S. &amp; Leclerc, M. Allogeneic hematopoietic stem cell transplantation in the COVID-19 era. Front. Immunol.14, 1100468 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9993088</ArticleId><ArticleId IdType="pubmed">36911678</ArticleId></ArticleIdList></Reference><Reference><Citation>Cesaro, S. et al. Update of recommendations for the management of COVID-19 in patients with haematological malignancies, haematopoietic cell transplantation and CAR T therapy, from the 2022 European Conference on Infections in Leukaemia (ECIL 9). Leukemia. ;37(9):1933-8. (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10457191</ArticleId><ArticleId IdType="pubmed">37460673</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. (2024). https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html</Citation></Reference><Reference><Citation>Krutikov, M. et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): Prospective cohort study in England. Lancet Healthy Longev.3(1), e13–e21 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8676418</ArticleId><ArticleId IdType="pubmed">34935001</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Dury, S. et al. Catch-up antibody responses and hybrid immunity in mRNA vaccinated patients at risk of severe COVID-19. Infect. Dis. (Lond). 55 (10), 744–750 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37395287</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazaruk, P. et al. Hybrid immunity provides the best COVID-19 humoral response in immunocompromised patients with or without SARS-CoV-2 infection history. Vaccines (Basel); 11(8). (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10458920</ArticleId><ArticleId IdType="pubmed">37631947</ArticleId></ArticleIdList></Reference><Reference><Citation>Agency) FtSPH. (2023). https://www.folkhalsomyndigheten.se/smittskydd-beredskap/utbrott/aktuella-utbrott/covid-19/statistik-och-analyser/bekraftade-fall-i-sverige/).</Citation></Reference><Reference><Citation>Sharma, A. et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol.8(3), e185–e93 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816949</ArticleId><ArticleId IdType="pubmed">33482113</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, L. et al. In-depth analysis of SARS-CoV-2-specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight; 7(7). (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057595</ArticleId><ArticleId IdType="pubmed">35230977</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, S. L. &amp; Flanagan, K. L. Sex differences in immune responses. Nat. Rev. Immunol.16(10), 626–638 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27546235</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>